A detailed history of Schonfeld Strategic Advisors LLC transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 420,800 shares of BCYC stock, worth $8.34 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
420,800
Previous 107,000 293.27%
Holding current value
$8.34 Million
Previous $1.93 Million 441.73%
% of portfolio
0.07%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$16.75 - $26.1 $5.26 Million - $8.19 Million
313,800 Added 293.27%
420,800 $10.5 Million
Q4 2023

Feb 14, 2024

BUY
$13.29 - $22.2 $729,621 - $1.22 Million
54,900 Added 105.37%
107,000 $1.93 Million
Q3 2023

Nov 14, 2023

SELL
$19.9 - $26.25 $278,600 - $367,500
-14,000 Reduced 21.18%
52,100 $1.05 Million
Q2 2023

Aug 14, 2023

BUY
$18.95 - $28.67 $113,700 - $172,020
6,000 Added 9.98%
66,100 $1.69 Million
Q1 2023

May 15, 2023

SELL
$20.02 - $31.37 $393,312 - $616,295
-19,646 Reduced 24.64%
60,100 $1.28 Million
Q4 2022

Feb 14, 2023

BUY
$20.37 - $32.9 $1.2 Million - $1.94 Million
58,946 Added 283.39%
79,746 $2.36 Million
Q3 2022

Nov 14, 2022

SELL
$17.49 - $28.44 $8,745 - $14,220
-500 Reduced 2.35%
20,800 $483,000
Q2 2022

Aug 15, 2022

BUY
$12.95 - $46.99 $172,235 - $624,967
13,300 Added 166.25%
21,300 $358,000
Q1 2022

May 16, 2022

BUY
$40.12 - $59.5 $320,960 - $476,000
8,000 New
8,000 $351,000
Q4 2021

Feb 14, 2022

SELL
$41.7 - $61.14 $2.5 Million - $3.67 Million
-59,972 Closed
0 $0
Q3 2021

Nov 16, 2021

BUY
$27.95 - $44.24 $142,824 - $226,066
5,110 Added 9.31%
59,972 $2.49 Million
Q2 2021

Aug 16, 2021

BUY
$27.0 - $32.28 $1.18 Million - $1.41 Million
43,762 Added 394.25%
54,862 $1.67 Million
Q1 2021

May 17, 2021

BUY
$19.12 - $30.25 $212,232 - $335,775
11,100 New
11,100 $331,000

Others Institutions Holding BCYC

About BICYCLE THERAPEUTICS plc


  • Ticker BCYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,676,100
  • Market Cap $588M
  • Description
  • Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...
More about BCYC
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.